

1 **Research ethics review during the COVID-19 pandemic:**  
2 **An international study**

3  
4  
5 **Fabio Salamanca-Buentello<sup>1</sup>, Rachel Katz<sup>2</sup>, Diego S. Silva<sup>3</sup>, Ross E.G. Upshur<sup>1,4</sup>, and Maxwell J.**  
6 **Smith<sup>5</sup>**

- 7  
8  
9 **1.** Bridgepoint Collaboratory for Research and Innovation, Lunenfeld-Tanenbaum Research  
10 Institute, Sinai Health, Toronto, Canada  
11 **2.** Institute for the History and Philosophy of Science and Technology, University of Toronto,  
12 Toronto, Canada  
13 **3.** School of Public Health, The University of Sydney, Sydney, Australia  
14 **4.** Dalla Lana School of Public Health, University of Toronto, Toronto, Canada  
15 **5.** Faculty of Health Sciences, Western University, London, Canada  
16

17  
18 **Corresponding Author:**

19 **Maxwell J. Smith, PhD**  
20 Assistant Professor  
21 School of Health Studies  
22 Faculty of Health Sciences  
23 Western University  
24 Room 331, Arthur and Sonia Labatt Health Sciences Building  
25 Phone: 519 661-2111 x88589  
26 Email: [maxwell.smith@uwo.ca](mailto:maxwell.smith@uwo.ca)  
27 ORCID: [0000-0001-5230-0548](https://orcid.org/0000-0001-5230-0548)  
28

## Research ethics review during the COVID-19 pandemic: An international study

29 **Author contributions:**

30

31 **Fabio Salamanca-Buentello**

32 Conceptualization, formal analysis, investigation, methodology, visualization, and writing (original  
33 draft).

34

35

36 **Rachel Katz**

37 Conceptualization, writing (review and editing).

38

39

40 **Diego S. Silva**

41 Conceptualization, funding acquisition, methodology, validation, and writing (review and editing).

42

43

44 **Ross E.G. Upshur**

45 Conceptualization, formal analysis, funding acquisition, investigation, methodology, supervision, and  
46 writing (review and editing).

47

48

49 **Maxwell J. Smith**

50 Conceptualization, funding acquisition, investigation, methodology, project administration, resources,  
51 supervision, validation, and writing (review and editing).

52

53 **ABSTRACT**

54

55           Research ethics review committees (ERCs) worldwide faced daunting challenges during the  
56 COVID-19 pandemic. There was a need to balance rapid turnaround with rigorous evaluation of high-  
57 risk research protocols in the context of considerable uncertainty. This study explored the experiences  
58 and performance of ERCs during the pandemic.

59

60 We conducted an anonymous, cross-sectional, global online survey of chairs (or their delegates) of  
61 ERCs who were involved in the review of COVID-19-related research protocols after March 2020. The  
62 survey ran from October 2022 to February 2023 and consisted of 50 items, with opportunities for open  
63 text responses.

64

65 Two hundred and three participants [130 from high-income countries (HICs) and 73 from low- and  
66 middle-income countries (LMICs)] completed our survey. Respondents came from diverse entities and  
67 organizations from 48 countries (19 HICs and 29 LMICs) in all World Health Organization regions.  
68 Responses show little of the increased global funding for COVID-19 research was allotted to the  
69 operation of ERCs. Few ERCs had pre-existing internal policies to address operation during public  
70 health emergencies, but almost half used existing guidelines. Most ERCs modified existing procedures  
71 or designed and implemented new ones but had not evaluated the success of these changes. Participants  
72 overwhelmingly endorsed permanently implementing several of them. Few ERCs added new members  
73 but non-member experts were consulted; quorum was generally achieved. Collaboration among ERCs  
74 was infrequent, but reviews conducted by external ERCs were recognized and validated. Review  
75 volume increased during the pandemic, with COVID-19-related studies being prioritized. Most

## Research ethics review during the COVID-19 pandemic: An international study

76 protocol reviews were reported as taking less than three weeks. One-third of respondents reported

77 external pressure on their ERCs from different stakeholders to approve or reject specific COVID-19-

78 related protocols.

79

80 ERC members faced significant challenges to keep their committees functioning during the pandemic.

81 Our findings can inform ERC approaches towards future public health emergencies. To our knowledge,

82 this is the first international, COVID-19-related study of its kind.

83

84

85

86 **INTRODUCTION**

87

88           The ethical review of research protocols during public health emergencies (PHEs) such as the  
89 COVID-19 pandemic is a daunting task. Committees tasked with assessing the ethical acceptability of  
90 research projects, which we refer to as ethics review committees (ERCs) but are also variably called  
91 research ethics boards, research ethics committees, ethics review boards, and institutional review  
92 boards, face challenges to reviewing research protocols swiftly while maintaining a high degree of  
93 rigour, all under suboptimal conditions and uncertainty. ERCs must balance the urge for rapid  
94 turnaround and flexibility with the requirement for intense scrutiny given that new projects often  
95 propose innovative but high-risk diagnostic, therapeutic, or preventive approaches to address the PHE.  
96 This is especially challenging in the case of countries with fragile health systems, poor infrastructure,  
97 and little experience conducting medical research, as well as countries experiencing protracted  
98 emergencies [1–5].

99

100 Failure to ensure rigour and depth during rapid ethics reviews in public health emergencies may place  
101 research participants at risk [6]. In such challenging circumstances, ERCs must consider how  
102 interventions, study design, eligibility criteria, community engagement, and approaches to vulnerable  
103 populations impact scientific validity, participant autonomy, respect for persons, welfare, justice, and  
104 social value [2,7–9]. Additional demands on ERCs may include the ability to incorporate and respond  
105 swiftly to newly available knowledge, provide monitoring and oversight of research, and considerations  
106 of the impact of the PHE on those involved in the research process, such as research participants,  
107 investigators, and ERC members and staff [7].

108

109 Public health emergencies force ERCs to make reasonable adjustments and design innovative strategies  
110 to address the various components of research ethics review while still adhering to ethical principles  
111 [3,6,7,10]. Moreover, after a PHE, changes implemented to secure continued operations of ERCs must  
112 be evaluated to determine their success and whether they should be permanently put in place to  
113 improve the everyday functioning of the committees.

114

115 Given the challenges that ERCs worldwide have faced during the COVID-19 pandemic, we aimed in  
116 this exploratory study to identify their experiences in the attempt to adapt to this PHE. We were  
117 particularly interested in the availability of pandemic-specific support, the promptness of protocol  
118 review, the volume of protocols received, the modifications to and innovations in operational  
119 procedures and policies and the evaluation of their outcomes, the anticipated permanence of such  
120 changes beyond the pandemic, the presence of pressure from different stakeholders on ERCs, the  
121 efforts to ensure quorum, the changes to the composition of ERCs, and the approaches to strengthen  
122 inter-ERC collaboration. To our knowledge, this is the first international, COVID-19-related study of  
123 its kind.

124

125

## 126 **METHODS**

127

128 This international, cross-sectional, exploratory online survey was conducted by researchers  
129 from Western University, the University of Toronto, and the Lunenfeld – Tanenbaum Research  
130 Institute in Canada, and the University of Sydney in Australia, in collaboration with the World Health  
131 Organization’s COVID-19 Ethics and Governance Working Group.

132

133 **Inclusion criteria**

134 We used targeted purposive and criterion sampling to invite Chairs and members of ERCs who were  
135 actively involved in the ethics review of COVID-19 research protocols to participate in this study. To  
136 ensure eligibility of participants, the first question of the survey asked respondents to confirm whether  
137 they had reviewed COVID-19-related research protocols during the pandemic. Responding to our  
138 survey was entirely voluntary. For the purposes of this study, we considered March 2020 as the  
139 beginning of this PHE. We specifically targeted individuals from all WHO regions. Participants were  
140 assigned to either of two categories: high-income countries (HICs) or low- and middle-income  
141 countries (LMICs), according to their reported country of residence. To do this, we used the World  
142 Bank classification of countries ([https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-  
143 world-bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups) ), which is based on gross national income per capita. We  
144 adopted this widely-used categorization notwithstanding its limitations in terms of hiding power  
145 imbalances and reducing important differences to questions of economics [11].

146

147 **Survey questionnaire**

148 The complete questionnaire is available as **S1 Appendix**. The overall structure and flow of the survey  
149 questionnaire, which consisted of a main “trunk” of 37 items organized into 11 thematic categories, is  
150 shown in **Error! Reference source not found.** Eight of these items branched into different survey  
151 flow elements based on respondents’ answers. Thus, in total, the questionnaire, written in English,  
152 included 50 questions. We privileged close-ended over open-ended questions, but we allowed  
153 respondents the opportunity to provide additional comments for some items. We pilot-tested the online

154 questionnaire with a small group of experts who fulfilled the inclusion criteria. This helped polish the  
155 wording of the questions and also assess and improve the logistics of the administration of the survey.

156

157 < **Fig. 1. Overall structure and flow of the survey questionnaire** >

158

### 159 **Data collection**

160 The invitation to participate in the survey explained the nature and purpose of our study, the inclusion  
161 criteria used to select participants, a summary of the procedures involved, and the URL link to the  
162 survey. These invitations were initially distributed by email by the WHO's COVID-19 Ethics and  
163 Governance Working Group through the email listserv of the 13th Global Summit of National Ethics  
164 Committees (an event that took place in September 2022). The Working Group identified additional  
165 potential participants among its extensive contact networks. We also circulated the invitation to experts  
166 identified by the research team. Invitations could also be forwarded to individuals designated by ERCs.  
167 In both cases, those invited fulfilled our inclusion criteria.

168

169 Our survey was active from October 11, 2022, to February 28, 2023. We used the Qualtrics Experience  
170 Management (XM) online platform to administer the questionnaire, which was open only to individuals  
171 who received the invitation with the link to the survey.

172

### 173 **Data analysis**

174 The analysis of the findings of this exploratory study employed descriptive statistics and stratified the  
175 comparison between responses of participants from HICs with those of participants from LMICs. To  
176 facilitate the examination of the results, tables were prepared showing the number and percentage of



177 respondents from HICs and LMICs who answered each question in the survey. Qualitative data (text  
178 responses from open-ended questions) were evaluated using thematic analysis and the constant  
179 comparative method.

180

### 181 **Research ethics approval**

182 Our study received approval from Western University’s Non-Medical Research Ethics Board (Protocol  
183 ID 120455). Additionally, it was evaluated by the World Health Organization Research Ethics Review  
184 Committee (Protocol ID CERC.0181) and was exempted from further review. The use of the Qualtrics  
185 platform facilitated data collection and management while respecting the privacy and confidentiality of  
186 participants. Respondents indicated their consent to participate in our survey by selecting a button  
187 labelled “I consent” at the end of the letter of information and consent, which appeared on the first page  
188 of the questionnaire. Responses were anonymous to protect participants’ privacy and confidentiality  
189 and encourage the open sharing of experiences.

190

191

## 192 **RESULTS**

193

### 194 **Characterization of survey respondents**

195 Two hundred and eighty-one individuals opened our survey. Of these, 250 answered the first  
196 question, which confirmed whether respondents fulfilled our inclusion criteria, and with which we  
197 could confirm their eligibility. Forty-three individuals explicitly indicated that they did not meet our  
198 criteria. Thus, the initial number of suitable respondents was 207. As expected in surveys such as ours

## Research ethics review during the COVID-19 pandemic: An international study

199 in which participants are allowed to skip questions, the number of respondents per question varied  
200 slightly, from a maximum of 207 to a minimum of 147.

201

202 Of the 204 participants who indicated their sex / gender, 120 (58.8%) were female, 82 (40.2%) were  
203 male, one (0.5%) preferred to self-describe, and one (0.5%) preferred not to disclose this information  
204 (**Box 1, Table a**). The proportion of females was higher in HICs (64.9%) than in LMICs (47.9%); thus,  
205 the distribution of respondents by sex / gender was more balanced in LMICs than in HICs. As shown in  
206 **Box 1, Table b**, more than three quarters of respondents (77.9%) were 45 years old or older. This was  
207 true for both HICs and LMICs. Most respondents provided ethics review for national bodies, such as  
208 national ethics committees or national public health organizations; more than a quarter participated in  
209 ERCs linked to academic or research institutions (**Box 1, Table c**). However, while almost half of  
210 respondents from HICs were members of ERCs affiliated with national bodies, only one quarter of  
211 participants from LMICs provided ethics review for such organizations. In contrast, in LMICs, 40% of  
212 respondents were members of ERCs associated with academic or research institutions. Furthermore,  
213 only 20% of participants from LMICs and 13.9% of participants from HICs provided ethics review for  
214 health care facilities.

215

216

**Research ethics review during the COVID-19 pandemic: An international study**

217 **Box 1.** Characterization of survey participants

**Table a.** Sex / gender of participants

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
<b>Female</b>	85	64.9	35	47.9	120	58.8
<b>Male</b>	44	33.6	38	52.1	82	40.2
<b>Prefer to self-describe</b>	1	0.8	0	0.0	1	0.5
<b>Prefer not to disclose</b>	1	0.8	0	0.0	1	0.5
<b>TOTAL</b>	131	100.0	73	100.0	204	100.0

**Table b.** Age of participants

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
<b>25 - 34 years old</b>	10	7.6	6	8.2	16	7.8
<b>35 - 44 years old</b>	13	9.9	16	21.9	29	14.2
<b>45 - 54 years old</b>	28	21.4	22	30.0	50	24.5
<b>55 - 64 years old</b>	31	23.7	18	25.0	49	24.0
<b>65+ years old</b>	47	35.9	10	13.7	57	27.9
<b>Prefer not to disclose</b>	2	1.5	1	1.4	3	1.5
<b>TOTAL</b>	131	100.0	73	100.0	204	100.0

**Table c.** Type of organization for which ethics review was provided

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
<b>National body</b>	89	44.3	24	25.3	113	38.2
<b>Academic institution or research institute</b>	40	19.9	38	40.0	78	26.4
<b>Health care facility</b>	28	13.9	19	20.0	47	15.9
<b>Private industry</b>	16	8.0	5	5.3	21	7.1
<b>Non-governmental organization</b>	9	4.5	4	4.2	13	4.4
<b>Sub-national governmental body</b>	9	4.5	2	2.1	11	3.7
<b>Ethics review committee not linked to another institution / organization</b>	6	3.0	0	0.0	6	2.0
<b>Other</b>	4	2.0	3	3.2	7	2.4
<b>TOTAL</b>	201	100.0	95	100	296	100.0

*Note: For this question, respondents could select more than one category. Therefore, "totals" refer to number of selections, not respondents*

## Research ethics review during the COVID-19 pandemic: An international study

219 In terms of the WHO region for which ethics review was provided, all regions were represented in our  
220 survey (**Table S 1**). More than one third of respondents reviewed research protocols from Europe,  
221 almost one fifth from the Americas, one tenth from Africa, and less than one tenth each from the other  
222 WHO regions.

223

224 **Table 1** shows the number of respondents by country of residence. Participants from 48 countries (19  
225 HICs and 29 LMICs) responded to our survey. Of the 203 individuals who indicated their country of  
226 residence, 130 (64%) were from HICs and 73 (36%) from LMICs. There was a large contingent of  
227 respondents from the UK (93).

228

229

## Research ethics review during the COVID-19 pandemic: An international study

230  
231  
232

**Table 1.** Number of respondents by country of residence

<b>Total number of countries: 48</b>			
<b>Total number of respondents who indicated country of residence: 203</b>			
<b>Respondents from 19 high-income countries (HICs)</b>		<b>Respondents from 29 low- and middle-income countries (LMICs)</b>	
Australia	1	Angola	1
Barbados	1	Argentina	6
Belgium	2	Bangladesh	1
Brunei Darussalam	1	Brazil	4
Canada	3	Cameroon	1
Chile	2	Colombia	1
Estonia	1	Costa Rica	2
France	1	Ecuador	1
Hungary	1	Egypt	1
Italy	1	El Salvador	2
Latvia	1	Ethiopia	2
New Zealand	1	Ghana	1
Panama	1	Grenada	2
Portugal	5	Honduras	1
San Marino	1	India	6
Singapore	6	Indonesia	1
South Korea	2	Iran	2
United Kingdom	93	Kenya	3
United States	6	Lebanon	1
		Liberia	1
		Malawi	2
		Malaysia	8
		Mexico	8
		Morocco	1
		Mozambique	1
		Pakistan	4
		Saint Vincent and the Grenadines	1
		South Africa	6
		Uganda	2
<b>TOTAL</b>	<b>130</b>	<b>TOTAL</b>	<b>73</b>

233  
234  
235

## Research ethics review during the COVID-19 pandemic: An international study

236

237 Two thirds of respondents had six or more years of experience as ERC members. This is true for  
238 participants from both HICs and LMICs (**Table S 2**).

239

240 As shown in **Table S 3**, about one half of respondents (52%) were involved in only one ERC. This  
241 pattern was common for participants from HICs and LMICs. However, more than one third of  
242 respondents from HICs participated in three or more ERCs during the COVID-19 pandemic. Of those  
243 who indicated involvement with multiple ERCs, close to one half specified that such participation was  
244 simultaneous (**Table S 4**).

245

### 246 **Support for the operation of ERCs during the pandemic**

247 As shown in **Table S 5**, an overwhelming majority (78.4%) of respondents indicated that their ERCs  
248 received no additional support for the operation of their committees during the pandemic. This lack of  
249 support was more pronounced in the case of ERCs in LMICs. For the minority of ERCs that did receive  
250 support, this consisted mainly of administrative and human resources, with one quarter of respondents  
251 from LMICs stating that their ERCs also received financial support, in contrast to only 12.5% of those  
252 from HICs (**Table S 6**). In terms of specific areas supported, participants from both HICs and LMICs  
253 mentioned teleconferencing and virtual meeting capabilities, information technology, support staff,  
254 assistance for ERC reviewers, and training of ERC members (**Table 2**). Interestingly, while 20% of  
255 respondents from HICs chose ERC support staff as one of the areas that received assistance, only 7.5%  
256 of those from LMICs did.

257

## Research ethics review during the COVID-19 pandemic: An international study

258

259 **Table 2.** Areas that received additional support during the COVID-19 pandemic

260

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
<b>Teleconferencing and virtual meeting capabilities</b>	23	28.0	8	20.0	31	25.4
<b>Ethics committee support staff</b>	16	19.5	3	7.5	19	15.6
<b>Information technology (IT) support</b>	12	14.6	6	15.0	18	14.8
<b>Ethics committee reviewers</b>	10	12.2	6	15.0	16	13.1
<b>Training of ethics committee members</b>	9	11.0	6	15.0	15	12.3
<b>Other administrative costs</b>	4	4.9	5	12.5	9	7.4
<b>Security for ethics committee members</b>	5	6.1	1	2.5	6	4.9
<b>External experts</b>	1	1.2	4	10.0	5	4.1
<b>Data management and storage</b>	1	1.2	1	2.5	2	1.6
<b>Other</b>	1	1.2	0	0.0	1	0.8
<b>TOTAL</b>	82	100.0	40	100.0	122	100.0

261

262 *Note: For this question, respondents could select more than one category. Therefore, "totals" refer*  
263 *to number of selections, not respondents*

264

265 In their text answers, participants alluded to support for covering the costs of using online platforms for

266 meetings and protocol review, and for acquiring or upgrading hardware such as laptops and webcams.

267 In one ERC, members were able to claim costs of setting up teleconferencing and of telephone calls if

268 dialling into a meeting. In other ERCs, information technology training was offered, along with

269 technical support for the use of online platforms. It is important to note that almost half of respondents

270 from HICs, but close to the totality (91.4%) of those from LMICs, indicated that their ERCs lacked any

271 pre-pandemic financial planning that included provisions for the support of the committees during a

272 public health emergency (**Table S 7**).

273

274

275

276 **Modification of existing procedures or policies**

277 Respondents from both HICs and LMICs overwhelmingly (more than 75% of participants in both  
278 cases) reported that their ERCs modified existing procedures or policies to operate during the pandemic  
279 (**Table S 8**). The most frequently modified domain was meeting logistics, followed by meeting  
280 frequency and procedures for protocol review and approval (**Table S 9**).

281

282 In terms of modifications to review procedures, several participants pointed out in their text responses  
283 that their ERCs fast-tracked the review of pandemic-related studies, shortening the timeline to review  
284 and approve protocols. ERC members were expected to complete the review of these protocols within a  
285 few days and, in some cases, 24 hours. To facilitate such a quick turnaround, some ERCs created  
286 special sub-committees that would conduct very fast protocol review. Moreover, participants  
287 emphasized the importance of simplifying and increasing the flexibility of administrative processes.  
288 For example, several respondents indicated that their ERCs switched entirely to the use of online  
289 platforms for protocol review, eliminating the need for paper documents.

290

291 Numerous participants stated that all ERC meetings were conducted virtually (as opposed to face-to-  
292 face) during the pandemic, which, in their view, enabled ERC members and researchers to participate  
293 regardless of geographical location, prevented contagion, and allowed rapid turnaround of reviews.  
294 Even in the case of virtual sessions, all other full meeting requirements such as quorum had to be met.  
295 Some ERCs modified their meetings to open a permanent slot in their agendas for COVID-19-related  
296 research or added urgent full meetings to discuss top-priority pandemic-related trial protocols. In other  
297 cases, members were permanently available to review COVID-19-related protocols, with those  
298 pertaining to other topics addressed less frequently.



299

300 While most respondents acknowledged the advantages of using online platforms during the pandemic  
301 to organize ERC meetings and to review research protocols, several participants highlighted the  
302 challenges that the use of such technologies entailed, particularly for new and more senior members of  
303 the ERCs who felt uncomfortable using these platforms. Some individuals deplored the loss of quality  
304 in the dynamics among ERC members (stilted conversations, fewer informal interactions) compared  
305 against the benefits of face-to-face meetings. Resistance to working online for some was compounded  
306 by difficulties accessing the internet and the lack of adequate electronic devices to do so.

307

308 Regarding the modification of protocol requirements, respondents mentioned the need to add safety  
309 procedures for study participants and members of the research teams, facilitating remote documentation  
310 of consent, and changing the policies regarding the use of non-anonymized data from health service  
311 and public health records for the duration of the pandemic to allow more unrestrained use of data.  
312 Some ERCs transitioned from requiring the physical signature of conflict-of-interest declaration forms  
313 to an email declaration.

314

315 As shown in **Table 3**, only a minority of respondents indicated that their ERCs conducted a formal  
316 evaluation of the success or failure of modifying existing procedures or policies (28% of participants  
317 from HICs and 17% of those from LMICs). More than one quarter of respondents did not know  
318 whether such modifications had been assessed.

319

320

321

## Research ethics review during the COVID-19 pandemic: An international study

322 **Table 3.** Evaluation of the success / failure of modifying existing procedures or policies  
323

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
<b>Yes</b>	24	27.9	8	17.0	32	24.1
<b>No</b>	36	41.9	29	61.7	65	48.9
<b>Unsure</b>	26	30.2	10	21.3	36	27.1
<b>TOTAL</b>	86	100.0	47	100.0	133	100.0

324

325

### 326 **Design and implementation of new procedures and policies**

327 Almost two-thirds of respondents from both HICs and LMICs reported that their ERCs had designed  
328 and implemented new procedures and policies to address the challenges brought about by the pandemic  
329 (**Table S 10**). As in the case of modifications to ERC processes, innovations occurred mainly in the  
330 areas of meeting logistics and frequency, and procedures for protocol review and approval (**Table S**  
331 **11**). This was the case for ERCs in both HICs and LMICs.

332

333 In their text responses, participants mentioned the development and implementation of new standard  
334 operating procedures (SOPs) and the integration of *ad hoc* committees, some including specialists, for  
335 urgent, accelerated protocol review. Such fast-track ERCs could review studies in one or two days,  
336 considerably shortening the time to complete reviews. One respondent considered the most successful  
337 innovation to be the formation of a “pool” of committee members ready to be convened at very short  
338 notice to quickly review COVID-19-related protocols. Such an *ad hoc* committee enabled applications  
339 to be reviewed and turned around very quickly.

340

## Research ethics review during the COVID-19 pandemic: An international study

341 The proportion of ERCs that formally evaluated the success or failure of new procedures and policies  
342 was analogous to that described for modifications to SOPs. **Table 4** shows that just 37% of respondents  
343 from HICs and 21% of those from LMICs reported that their ERCs conducted such an evaluation.

344

345 **Table 4.** Evaluation of the success / failure of designing and implementing new procedures or policies

346

	HICs		LMICs		TOTAL	
	n	%	n	%	n	%
<b>Yes</b>	25	37.3	8	21.6	33	31.7
<b>No</b>	26	38.8	26	70.3	52	50.0
<b>Unsure</b>	16	23.9	3	8.1	19	18.3
<b>TOTAL</b>	67	100.0	37	100.0	104	100.0

347

348

### 349 **Permanently putting into effect modifications and innovations**

350 A substantial majority of respondents (almost three quarters of those from HICs and more than four-  
351 fifths of those from LMICs) stated that many of the modifications and innovations to operating  
352 procedures implemented during the pandemic should be permanently put into effect (**Table S 12**),  
353 particularly in the areas of meeting logistics and frequency, procedures for protocol review and  
354 approval, and training of ethics review committee members in new or modified procedures (**Table S**  
355 **13**). Several participants argued in their text responses that virtual online meetings should be a  
356 permanent feature of ERC operations, as they increase efficiency and preclude many of the  
357 disadvantages of face-to-face meetings. Another recommendation was to enable the integration of *ad*  
358 *hoc* committees during times of increased demand. Similarly, respondents emphasized the relevance of  
359 facilitating the incorporation of new expert members to the ERCs as required. However, 20% of  
360 participants from HICs and 50% of those from LMICs indicated that their ERCs had no support to

361 permanently implement modifications or innovations established during the COVID-19 pandemic  
362 (**Table S 14**).

363  
364 **Policies, procedures, and guidelines for public health emergencies**

365 It is noteworthy that almost half of respondents from HICs and three-quarters of participants from  
366 LMICs indicated that their ERCs did not have internal policies, procedures, or guidelines before the  
367 pandemic that could orient members regarding the functioning of the committees during PHEs (**Table**  
368 **S 15**). Regarding the use of internal guidelines, some ERCs adapted existing documents, while others  
369 developed entirely new procedures. In the absence of specific internal guidelines, some SOPs explicitly  
370 privileged expedited review during health crises.

371  
372 In contrast to the widespread absence of internal guidelines, the ERCs of one quarter of respondents  
373 from HICs and of almost half of those from LMICs used external guidelines not developed by their  
374 committees to govern their operation during the pandemic (**Table S 16**). Members of several  
375 committees referred to publicly available national and international guidelines. A selection of the most  
376 consulted documents appears in **Box 2**.

377

378

379 **Box 2.** National and international external guidelines\* that survey respondents reported were used by  
380 their ERCs to manage operations during the COVID-19 pandemic

381

#### **International Health Organizations**

- Council for International Organizations of Medical Sciences, & World Health Organization (2016). International Ethical Guidelines for Health-related Research Involving Humans (Fourth Ed.). Council for International Organizations of Medical Sciences. <https://doi.org/10.56759/rgxl7405>
- Pan-American Health Organization (2020). Guidance for ethics oversight of COVID-19 research in response to emerging evidence. <https://iris.paho.org/handle/10665.2/53021>
- Pan-American Health Organization (2020). Guidance and strategies to streamline ethics review and oversight of COVID-19-related research. <https://iris.paho.org/handle/10665.2/52089>
- Pan-American Health Organization (2020). Template and operational guidance for the ethics review and oversight of COVID-19-related research. <https://iris.paho.org/handle/10665.2/52086>
- Pan-American Health Organization (2022). Catalyzing ethical research in emergencies. Ethics guidance, lessons learned from the COVID-19 pandemic, and pending agenda. <https://iris.paho.org/handle/10665.2/56139>
- Red de América Latina y el Caribe de Comités Nacionales de Bioética - United Nations Educational, Scientific and Cultural Organization (UNESCO) (2020). Ante las investigaciones biomédicas por la pandemia de enfermedad infecciosa por coronavirus Covid-19. <https://redbioetica.com.ar/wp-content/uploads/2020/03/Declaracion-RED-ALAC-CNBS-Investigaciones-Covid-19.pdf>
- World Health Organization (2016). Guidance for managing ethical issues in infectious disease outbreaks. World Health Organization. <https://apps.who.int/iris/handle/10665/250580>
- World Health Organization (2020). Key criteria for the ethical acceptability of COVID-19 human challenge studies. <https://apps.who.int/iris/handle/10665/331976>
- World Health Organization (2020). Guidance for research ethics committees for rapid review of research during public health emergencies. <https://apps.who.int/iris/handle/10665/332206>
- World Health Organization (2020). Ethical standards for research during public health emergencies: distilling existing guidance to support COVID-19 R&D. <https://apps.who.int/iris/handle/10665/331507>

#### **Bioethics centres**

- Nuffield Council of Bioethics (2020). Ethical considerations in responding to the COVID-19 pandemic. <https://www.nuffieldbioethics.org/assets/pdfs/Ethical-considerations-in-responding-to-the-COVID-19-pandemic.pdf>
- The Hastings Center: Berlinger N *et al.* (2020). Ethical Framework for Health Care Institutions Responding to Novel Coronavirus SARS-CoV-2 (COVID-19). Guidelines for Institutional Ethics Services Responding to COVID-19. <https://www.thehastingscenter.org/ethicalframeworkcovid19/>

#### **Scientific publications mentioned by respondents**

- Saxena *et al.* (2019). Ethics preparedness: facilitating ethics review during outbreaks - recommendations from an expert panel. <https://bcmcedethics.biomedcentral.com/articles/10.1186/s12910-019-0366-x>

#### **National guidelines**

##### **Argentina**

- Resolución 908/2020. Ministerio de Salud de Argentina: <https://www.argentina.gob.ar/normativa/nacional/resoluci%C3%B3n-908-2020-337359/texto>

##### **Brazil**

- Normativas da Comissão Nacional de Ética em Pesquisa: <http://conselho.saude.gov.br/normativas-conep?view=default>

##### **Costa Rica**

- Consejo Nacional de Investigación en Salud de Costa Rica (CONIS) (2020). COMUNICADO 2: Recomendaciones para realizar investigación biomédica durante el periodo de la emergencia sanitaria por COVID-19 en Costa Rica. [https://www.ministeriodesalud.go.cr/gestores\\_en\\_salud/conis/circulares/comunicado\\_cec\\_oac\\_oic\\_20082020.pdf](https://www.ministeriodesalud.go.cr/gestores_en_salud/conis/circulares/comunicado_cec_oac_oic_20082020.pdf)

## Research ethics review during the COVID-19 pandemic: An international study

### ***El Salvador***

- Comité Nacional de Ética de la Investigación en Salud de El Salvador (2015). Manual de procedimientos operativos estándar para comités de ética de la investigación en salud. <https://www.cneis.org.sv/wp-content/uploads/2018/07/MANUAL-CNEIS.pdf>

### ***India***

- Indian Council of Medical Research (2017). National ethical guidelines for biomedical and health research involving human participants. [https://ethics.ncdirindia.org/asset/pdf/ICMR\\_National\\_Ethical\\_Guidelines.pdf](https://ethics.ncdirindia.org/asset/pdf/ICMR_National_Ethical_Guidelines.pdf)
- Indian Council of Medical Research (2020). National guidelines for ethics committees reviewing biomedical & health research during COVID-19 pandemic. [https://main.icmr.nic.in/sites/default/files/guidelines/EC\\_Guidance\\_COVID19\\_06\\_05\\_2020.pdf](https://main.icmr.nic.in/sites/default/files/guidelines/EC_Guidance_COVID19_06_05_2020.pdf)

### ***Kenya***

- Kenya Medical Research Institute Scientific and Ethics Review Unit (2019). KEMRI SERU guidelines for the conduct of research during the covid-19 pandemic in Kenya. [https://www.kemri.go.ke/wp-content/uploads/2019/11/KEMRI-SERU\\_GUIDELINES-FOR-THE-CONDUCT-OF-RESEARCH-DURING-THE-COVID\\_8-June-2020\\_Final.pdf](https://www.kemri.go.ke/wp-content/uploads/2019/11/KEMRI-SERU_GUIDELINES-FOR-THE-CONDUCT-OF-RESEARCH-DURING-THE-COVID_8-June-2020_Final.pdf)

### ***Malaysia***

- Garis Panduan Pengurusan COVID-19 di Malaysia No.5 [COVID-19 Management Guidelines in Malaysia No.5 ] (2020). Ministry of Health of Malaysia. <https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm>

### ***Pakistan***

- Government of Pakistan National COVID Command and Operation Center (NCO) Guidelines (2020). [No longer available, as NCO ceased operations on April 1, 2022]

### ***South Africa***

- Department of Health, Republic of South Africa (2015). Ethics in Health Research: Principles, Processes and Structures (2d Ed). <https://www.sun.ac.za/english/research-innovation/Research-Development/Documents/Integrity%20and%20Ethics/DoH%202015%20Ethics%20in%20Health%20Research%20-%20Principles,%20Processes%20and%20Structures%202nd%20Ed.pdf>

### ***South Korea***

- Government of the Republic of Korea (2014). Bioethics and Safety Act (Act No. 12844). [https://elaw.klri.re.kr/eng\\_mobile/viewer.do?hseq=33442&type=part&key=36](https://elaw.klri.re.kr/eng_mobile/viewer.do?hseq=33442&type=part&key=36)

### ***United Kingdom***

- United Kingdom Health Departments / Research Ethics Service (2022). Standard Operating Procedures for Research Ethics Committees (Version 7.6). [https://www.hra.nhs.uk/documents/3090/RES\\_Standard\\_Operating\\_Procedures\\_Version\\_7.6\\_September\\_2022\\_Final.pdf](https://www.hra.nhs.uk/documents/3090/RES_Standard_Operating_Procedures_Version_7.6_September_2022_Final.pdf). [In particular, several respondents from the UK mentioned Section 9 of this document, which addresses expedited review in situations such as public health emergencies.]
- Health Research Authority (2020). <https://www.hra.nhs.uk/approvals-amendments/>
- Health Research Authority (2020). <https://www.hra.nhs.uk/covid-19-research/covid-19-guidance-sponsors-sites-and-researchers/>
- Department of Health and Social Care (2020). Coronavirus (COVID-19): notification to organisations to share information. <https://www.gov.uk/government/publications/coronavirus-covid-19-notification-of-data-controllers-to-share-information>

382 *\*We defined “external guidelines” as those not developed internally by participants’ ERCs*

383

384

### 385 **Changes in workload**

386 Respondents stated that the workload of ERC members increased considerably during the pandemic,

387 both because of the increase in the number of protocols reviewed and due to the urgency that the

## Research ethics review during the COVID-19 pandemic: An international study

388 approval of COVID-19-related studies demanded. More than half of participants indicated that the  
389 volume of protocols received for review increased, both for studies assigned to delegated / expedited  
390 review, and for protocols that underwent full review (**Table S 17**). The increase in the volume of  
391 protocols had unexpected consequences. For example, in one HIC, the number of applicants who were  
392 summoned to discuss their protocols with ERCs in online meetings increased proportionally to the  
393 escalation in the volume of protocols submitted. In another case, ERC members were burdened with  
394 additional tasks such as working closely with the investigators of rejected COVID-19 protocols to  
395 improve their applications until these could be approved.

396

397 In terms of the time it took ERCs to process and approve protocols during the pandemic, respondents  
398 confirmed in their text answers that the turnaround time for ERC review was markedly shortened, from  
399 weeks or even months to just a few days. In general, more than half of survey participants indicated  
400 that, before the pandemic, the duration of the review process, from the time of initial submission to full  
401 approval, was between three and eight weeks (**Table S 18**). In contrast, during the pandemic, this  
402 process was substantially reduced to less than two weeks for both delegated / expedited review and full  
403 review. However, this decrease was more pronounced in HICs than in LMICs (**Table S 19**).

404 Unsurprisingly, the approval of COVID-19-related research protocols was faster than that of non-  
405 COVID-19 studies. More than two-thirds of respondents indicated that delegated / expedited review of  
406 COVID-19-related protocols took less than five weeks; this was the case for more than half of full  
407 reviews. The process was longer in LMICs, though (**Table S 20**). Conversely, protocol review was  
408 slightly longer for non-COVID-19 studies, except in the case of full reviews in LMICs, which  
409 participants reported took between three and more than 12 weeks (**Table S 21**).

410

411 **Presence of external pressure on ERCs**

412 While only 14% of respondents from HICs reported that their ERCs were subjected to different types  
413 of external pressure to both approve and reject research protocols, one third of participants from LMICs  
414 (34%) faced such a challenge (**Table S 22**). The most frequent perceived demand involved pressures to  
415 rush studies through the review process at the expense of proper examination and ethical oversight.  
416 This was especially evident in the case of COVID-19 vaccine clinical trials. Some participants  
417 highlighted their defense of the autonomy of their ERCs in the face of external influences by using, for  
418 example, research policies developed and implemented specifically for the pandemic as a tool for  
419 transparent decision-making and as a safeguard against external pressures. One ERC successfully  
420 resisted government pressure to approve a research protocol related to a domestic PCR test, human  
421 trials of locally developed ventilators, and a placebo-controlled vaccine trial proposed despite the  
422 existence of six emergency-authorized vaccines and ongoing mass vaccination.

423

424 While some respondents acknowledged that entities such as national governments were understandably  
425 impatient for preventive, diagnostic, and therapeutic measures to combat the pandemic, they still  
426 emphasized the need for proper and thorough review of research protocols. One respondent stated that  
427 institutional authorities that favoured or sponsored certain studies sought their immediate approval and  
428 considered ERCs as inconvenient hindrances to achieve this goal. Several participants described  
429 instances in which ERCs, particularly in LMICs, received pressure to approve alternative medicine  
430 clinical trials.

431

432

433



434 **Types of COVID-19 protocols reviewed by ERCs**

435 Given the range of challenges brought about by the COVID-19 pandemic, it was interesting to  
436 determine the proportion of protocols received by ERCs according to the research area in which they  
437 could be classified, namely, diagnostics, therapeutics, vaccines, pharmacovigilance, or other topics  
438 such as behavioural research. Our results suggest that between one-half and two-thirds of ERCs  
439 received from one to 10 studies in each area (**Table 5**). In other words, all areas of COVID-19 research  
440 were covered in these protocols in ERCs of both HICs and LMICs. However, it must be noted that  
441 between one-third and one-half of respondents could not classify the protocols received by their ERCs  
442 (perhaps due to not tracking such information).

443

444 **Table 5.** Number of COVID-19 protocols reviewed, by type of study

445

446

	Diagnostics		Therapeutics		Vaccines		Pharmacovigilance		Other											
	HICs		LMICs		HICs		LMICs		HICs		LMICs									
	n	%	n	%	n	%	n	%	n	%	n	%								
<b>0</b>	10	22.2	8	25.0	10	19.6	8	22.9	10	22.2	8	24.2	10	27.8	7	25.9	9	20.5	7	20.0
<b>1 to 10</b>	29	64.4	19	59.4	27	52.9	17	48.6	24	53.3	16	48.5	20	55.6	13	48.1	23	52.3	16	45.7
<b>11 to 20</b>	5	11.1	3	9.4	5	9.8	3	8.6	4	8.9	3	9.1	4	11.1	3	11.1	4	9.1	3	8.6
<b>21 to 30</b>	0	0.0	2	6.3	0	0.0	2	5.7	0	0.0	2	6.1	0	0.0	1	3.7	0	0.0	1	2.9
<b>&gt; 30</b>	1	2.2	0	0.0	1	2.0	0	0.0	1	2.2	0	0.0	1	2.8	0	0.0	1	2.3	0	0.0
<b>No response</b>	0	0.0	0	0.0	8	15.7	5	14.3	6	13.3	4	12.1	1	2.8	3	11.1	7	15.9	8	22.9
<b>TOTAL</b>	<b>45</b>	<b>100</b>	<b>32</b>	<b>100</b>	<b>51</b>	<b>100</b>	<b>35</b>	<b>100</b>	<b>45</b>	<b>100</b>	<b>33</b>	<b>100</b>	<b>36</b>	<b>100</b>	<b>27</b>	<b>100</b>	<b>44</b>	<b>100</b>	<b>35</b>	<b>100</b>

447

448

449 **Prioritization of protocols for ethics review**

450 Overwhelmingly, and as expected, participants reported that their ERCs considered COVID-19-related  
451 protocols urgent and thus prioritized their review and approval over that of others, particularly in terms  
452 of expediting the review of these studies and privileging their discussion during committee meetings.  
453 More than three quarters of respondents from HICs and almost two-thirds of those from LMICs  
454 indicated that their ERCs gave priority to COVID-19-related studies (**Table S 23**). In fact, in one case,  
455 an ERC stopped reviewing non-COVID-19-related protocols altogether. Some ERCs gave precedence  
456 to the review of COVID-19-related studies according to the priorities determined by their national  
457 governments. Others were assigned studies by an *ad hoc* national entity that triaged the research  
458 protocols. Interestingly, however, as shown in **Table S 23**, 15% of respondents from HICs and 27% of  
459 those from LMICs stated that their ERCs did not give priority to pandemic-related studies.

460  
461 Furthermore, our results show that almost one-third of respondents from HICs and almost half of those  
462 from LMICs indicated that, for their ERCs, the review of some types of COVID-19-related studies took  
463 precedence over that of others (**Table S 24**). In their text responses, participants explicitly mentioned  
464 prioritizing clinical trials, particularly those focused on COVID-19 vaccine development and safety  
465 monitoring; studies related to therapeutic agents for the treatment of COVID-19; protocols about  
466 diagnostics and prognostic factors; epidemiological studies, including those related to the natural  
467 history of COVID-19 and serosurveillance; and research affecting public health policy. In the case of  
468 one ERC in a HIC with very low infection rates resulting from successful public health measures,  
469 priority was given to vaccine trials and observational research on vaccine monitoring and community  
470 incidence.

471 **Membership of ERCs during the pandemic**

472 One of the main challenges that ERCs worldwide faced during the pandemic was making certain that  
473 the number and expertise of their members enabled the efficient operation of the committees under  
474 such demanding circumstances. Most survey respondents indicated that their ERCs were able to ensure  
475 quorum (80% of participants from HICs, but only 60% of those from LMICs); however, one-third of  
476 respondents from LMICs stated that quorum in their ERCs was infrequently met (**Table S 25**). Two-  
477 thirds of participants from HICs and three quarters of those from LMICs reported that their committees  
478 had taken measures to ensure continuity of adequate review of research protocols in case existing  
479 members became unavailable due to the pandemic (**Table S 26**).

480

481 ERCs in both HICs and LMICS did invite new members or appointed alternate ones to ensure quorum  
482 and inclusion of individuals with appropriate expertise. Yet, consulting expert non-members seems to  
483 have been preferred to incorporating individuals to the committee. Only 13% of respondents from HICs  
484 and 24% of those from LMICs indicated that their ERCs had added new members to accelerate  
485 protocol review during the pandemic (**Table S 27**). Similarly, 11% of participants from HICs and 37%  
486 of those from LMICs added new members with specific expertise (**Table S 28**). In contrast, almost  
487 one-third of individuals from HICs, but close to two-thirds of those from LMICs, stated that their  
488 committees had consulted expert non-members to address novel areas of research or provide enhanced  
489 scrutiny of research protocols (**Table S 29**). In their text responses, participants expressed that, in some  
490 cases, ERCs incorporated new members available at quick notice and who were comfortable with the  
491 use of online platforms for meetings and protocol review. A similar approach consisted of integrating  
492 virtual *ad hoc* committees solely to review COVID-19-related-protocols. For some ERCs, national

493 legislation complicated getting additional support or adding new members. Another factor complicating  
494 the integration of ERCs was that clinical responsibilities of individuals directly in the care of COVID-  
495 19 patients soared, hindering their participation in committee meetings. One participant reported that  
496 some ERC members could not fulfill their duties in the ERC because they had become highly sought-  
497 after “media celebrity” experts.

498

499 Survey respondents suggested that it would be worthwhile to assess the psychological and emotional  
500 challenges that ERC members faced by having to evaluate protocols using new, unfamiliar procedures  
501 under extreme pressure. Also, it is worth reiterating that, according to several participants, many ERC  
502 members, particularly older ones, deplored the loss of features common to face-to-face meetings, such  
503 as a warmer, more informal and welcoming environment that favoured interpersonal interactions. Other  
504 respondents expressed their desire for constructive and supportive feedback and for more appreciative  
505 and generous gestures of gratitude for the extraordinary efforts of ERCs. However, a few participants  
506 considered that being able to respond in a useful way to a public health crisis as ERC members was  
507 very gratifying and validating.

508

### 509 **National and international collaboration**

510 While ~40% of respondents from HICs and LMICs reported the presence of national and international  
511 collaboration among ERCs to standardize emergency operations and procedures during the pandemic,  
512 almost one-third of participants from HICs were unsure about the existence of such collaboration  
513 (**Table S 30**). Almost half of respondents from HICs, but more than two-thirds of those from LMICs,  
514 indicated that their ERCs did not have strategies to harmonize multiple review processes (**Table S 31**).

515 Most participants (55% of those from HICs and 63% of those from LMICs) reported that their ERCs  
516 relied on established procedures to recognize and validate research protocol reviews conducted by  
517 other committees (**Table S 32**). About one half of respondents from HICs, but almost two-thirds of  
518 those from LMICs, affirmed that their ERCs collaborated with scientific committees that pre-reviewed  
519 or prioritized pandemic-related research protocols (**Table S 33**).

520

521 Almost 50% of participants from HICs, but little more than a third of those from LMICs, reported the  
522 presence of centralized ethics review of research protocols for multicentre studies related to COVID-19  
523 (**Table S 34**). Conversely, one-third of respondents from HICs, but more than two-thirds of those from  
524 LMICs, stated that their ERCs did not consider the formation of Joint Scientific Advisory Committees,  
525 Data Safety Review Committees, Data Access Committees, or a Joint Ethics Review Committee with  
526 representatives of ethics committees of all institutions and countries involved in COVID-19-related  
527 research (**Table S 35**).

528

529 In their text responses, participants noted the need for better inter-ERC collaboration and  
530 communication at the national and international levels to share successful strategies and avoid effort  
531 duplication. A case of very successful national inter-ERC collaboration is worth mentioning.

532 Respondents from one particular LMIC stated that, given the critical absence of the national entity  
533 responsible for health research ethics during the pandemic, ERCs throughout the country joined forces  
534 to create an *ad hoc* spontaneous informal national network of all ERC chairs and co-chairs (it also  
535 included members of the national drug regulator) to strengthen mutual support, enhance  
536 communication among ERCs, identify best practices, and share academic and ethics resources.

537 **DISCUSSION**

538

539 ERCs faced considerable challenges during the COVID-19 pandemic. Demands were placed on  
540 them to urgently review an increased volume of protocols while maintaining rigour, all under  
541 suboptimal conditions and uncertainty. Yet, our findings suggest ERCs reviewed a greater volume of  
542 protocols and did so faster than before the pandemic. Against this backdrop, our results also reveal that,  
543 despite billions of dollars having been invested into the R&D ecosystem to support the COVID-19  
544 research response, little to no additional resources were directed to ERCs to support and/or expedite  
545 their functions. This should be particularly sobering for those who raise complaints about ERCs being  
546 an “obstacle” to research [12–15]. It may also help to explain other challenges experienced by ERCs  
547 during the pandemic, such as the absence of internal policies or guidelines for adapting to a PHE, the  
548 collateral damage sustained from deprioritizing non-COVID-19 protocols, and the pressures felt to rush  
549 protocols through review.

550

551 Our finding that ERCs wish to sustain many of the modifications made to their operations during the  
552 COVID-19 pandemic should be interpreted in light of the fact that ERCs also report having received  
553 little or no support during the COVID-19 pandemic as well as exiguous support for the maintenance of  
554 any modifications they wish to make permanent into the future. If it is expected that our research ethics  
555 ecosystem learns from this experience and enhances operations for future threats, it is difficult to see  
556 how this will be possible without significant investment. While no one seems to disagree that the  
557 research ethics ecosystem should strive for greater efficiency and collaboration, especially during  
558 PHEs, investments are required to achieve these aims. Simply put, the experience of ERCs during the

559 COVID-19 pandemic, while herculean in many respects, was a function of necessity and is unlikely to  
560 be sustainable.

561

562 Extant literature reporting the challenges faced by ERCs during the COVID-19 pandemic is scant and  
563 tends to be limited to the early phases of this PHE. Most studies published on this topic are confined to  
564 single countries or geographical regions, with only one study including 14 countries in Africa, Asia,  
565 Australia, and Europe[16]. Several of these contributions focus exclusively on one ERC, usually  
566 associated with an academic or health care institution. The literature includes descriptions of ERC  
567 operations during the pandemic in Central America and the Dominican Republic [17], China [18],  
568 Ecuador [19], Egypt [20], Germany [21], India [22–24], Iran [10], Ireland [25], Kenya [26],  
569 Kyrgyzstan [27], Latin America [28], the Netherlands [29], Pakistan [30], South Africa [31,32], Turkey  
570 [33], and the United States [34–36]. Most of these studies reported results from surveys, interviews,  
571 focus groups, and documentary analysis, including review of research protocols, ERC meeting minutes,  
572 and existing SOPs. Participants usually consisted of ERC chairpersons and members, clinical and  
573 biomedical researchers, institutional representatives, and laypeople. Most studies based on surveys and  
574 interviews included fewer than 30 respondents, with only some having more than 100 participants.

575

576 Our findings agree with this literature. Given that our study is truly global in scope, it considerably  
577 broadens what is known about the operation of ERCs during the COVID-19 pandemic and clears a path  
578 towards greater consensus on strategies to prepare for and respond during future PHEs.

579



580 In this literature, several studies emphasize the lack of support and resources to operate during the  
581 pandemic. The vast majority of ERCs made numerous modifications to their SOPs. In particular, the  
582 use of online platforms for ERC meetings and for protocol review was ubiquitous. However, ERC  
583 members across studies pointed out several disadvantages of such platforms, including lack of  
584 familiarity and technical know-how, particularly in the case of more senior members of the committees.  
585 Only a few institutions provided training, equipment, and technical support for the use of these online  
586 platforms. Consistent with our findings, almost no ERCs in these studies reported having internal  
587 policies, procedures, or guidelines to operate during a PHE. National regulations on this topic, where  
588 available, were often unclear, contradictory, rapidly changing, vague, or difficult to interpret.  
589 Conversely, several ERCs availed themselves of international guidelines (Box 2), in particular those  
590 prepared by WHO [37–40] and PAHO [41–44].

591

592 In terms of changes in workload, all ERCs in the studies mentioned earlier experienced a dramatic  
593 increase in the number of COVID-19-related protocols received, which had to be reviewed very  
594 quickly in the face of pressure from researchers, institutions, governments, and the media for expedited  
595 approvals. The surge in the volume of protocols, along with shortened timelines for turnaround,  
596 severely strained ERC members' ability to conduct rigorous, thorough, high-quality assessments.  
597 Despite feeling overwhelmed, ERC members participating in these studies managed to fulfill their  
598 responsibilities, sometimes at great personal cost.

599

600 Given the urgency to examine and approve an ever-increasing number of COVID-19 research  
601 protocols, the studies report several strategies implemented by ERCs worldwide to prioritize their

602 review. This frequently meant that the assessment of non-COVID-19-related studies was postponed or  
603 even abandoned. Similarly, non-interventional COVID-19 protocols were given secondary importance.  
604 Prioritization of COVID-19 protocols by type of study was rare.

605

606 Despite numerous staffing challenges, most ERCs in the studies examined were able to ensure quorum.  
607 In some cases, their institutions provided training sessions to update committee members on the rapidly  
608 changing landscape of basic and clinical knowledge about COVID-19. A less frequently used approach  
609 was to incorporate new members with relevant expertise into the ERCs. One common strategy across  
610 different countries was the integration of *ad hoc* committees focused exclusively on the review of  
611 COVID-19 -related protocols.

612

613 The topic of centralized review of pandemic-related research is rather contentious in this literature.  
614 While some studies report ERC members favouring such an approach, others consider that a single  
615 national ERC in charge of PHE-specific ethics review is bound to be unsuccessful due to the  
616 importance of local context in responding to PHEs. In Ecuador, forcing researchers to submit their  
617 protocols to a seven-member centralized *ad hoc* ERC caused considerable delays in the approval  
618 process and instead severely impeded the execution of COVID-19-related studies [19].

619

620 As shown in our results, in some countries ERCs strengthened collaboration networks during the  
621 pandemic. A notable case was the creation of a spontaneous, informal, *ad hoc* group in South Africa—  
622 the Research Ethics Support in COVID-19 Pandemic (RESCOP)—by ERC chairpersons and members  
623 as a response to the lack of national ethics guidance and the unexpected critical absence of the National

624 Health Research Ethics Council at the most crucial moment in the pandemic [32]. This example  
625 highlights the clear need for national governance and oversight for research ethics to ensure  
626 accountability and responsiveness of ERCs [45].

627

628 A common topic of concern across ERCs in several countries was the set of unique challenges to  
629 obtaining informed consent during the pandemic, especially in the case of patients unable to give  
630 consent, such as those who were severely ill, isolated, or in the intensive care unit. Thus, it was  
631 necessary to find innovative alternative strategies to obtain consent.

632

633

634 **RECOMMENDATIONS**

635

636 **Box 3.** Recommendations to strengthen the resiliency of ERCs during future public health emergencies.

637

- Increase and assign an adequate proportion of the budgets of ERCs for:
  - Their continued operation during PHEs, especially in terms of online teleconferencing and review platforms
  - Sustaining select modifications and innovations designed and implemented during PHEs
- Increase awareness of the value of ERCs in the research and development (R&D) ecosystem as a means of protecting research participants, ensuring social value, and promoting public trust in research outputs, rather than as a bureaucratic nuisance
- Evaluate the success or failure of modifications and innovations designed and implemented during PHEs
- Develop a “first aid kit” for each ERC that includes:
  - Existing external guidelines for committee operation during a PHE
  - Internal contingency plans designed by the ERC or its home institution that adapt existing external guidelines to local contexts
  - A directory of expert non-members available for consultation
  - Easy-to-follow checklists that incorporate the essential elements needed to function during a PHE
- Familiarize ERC members with the “first aid kit” through periodic capacity building activities
- Consider the psychological and emotional challenges that ERC members face during PHEs
- Devise strategies to defend and safeguard ERCs’ autonomy against external pressures
- Promote national and regional collaboration networks of ERCs that strengthen their resiliency during PHEs
- Facilitate collaboration between ERCs and scientific committees

638

639

640 **LIMITATIONS AND STRENGTHS**

641

642 In terms of the limitations of our study, it would have been desirable to include participants  
643 from more countries, and a larger number of respondents from each country. It was probably difficult  
644 to reach a higher response rate due to “pandemic fatigue”. Non-native English speakers, especially in  
645 LMICs, may have excluded themselves from our survey. Absent or unreliable internet access could

646 have limited the participation of some participants, particularly in LMICs. The number of ERC  
647 members that provided ethics review for health care facilities was relatively low. Despite the  
648 anonymity of their answers, respondents may have been reluctant to share specific instances of external  
649 pressures impinging upon their ERCs. The large number of participants from the UK (93 out of 281)  
650 likely skewed the results from HICs, and from experiences in the UK in particular.

651

652 We chose to present our results descriptively and did not perform any analytic tests for statistically  
653 significant differences in responses. This was because we were unable to determine a denominator, so  
654 we could not meet the requirements for many significance tests. Non-parametric tests could have been  
655 used, but we think reporting statistical significance in this context would not be informative. Non-  
656 response bias could also influence our results. This could be non-differential in its effects as our results  
657 cohere with the literature thus far reported.

658

659 To our knowledge, this is the first examination at a global level of the challenges faced by ERCs during  
660 the COVID-19 pandemic, and the strategies used to address them. Also, our study compares for the  
661 first time several dimensions of the operation of ERCs during the pandemic between committees in  
662 HICs and those in LMICs. All WHO regions were represented in our study, as participants from 48  
663 countries (19 HICs and 29 LMICs) responded to our survey. There was an adequate balance in terms of  
664 the sex / gender of respondents. Furthermore, the ample experience of the study participants as ERC  
665 members (two thirds of respondents had six or more years of experience in this role) strengthens the  
666 generalizability of our findings. The recommendations suggested by the study participants are quite

667 relevant to combating future public health emergencies. In general, all these strengths give credence to  
668 the validity, reliability, and accuracy of our results.

669

## 670 **ACKNOWLEDGEMENTS**

671

672 We are very grateful to all the members of ethics review committees who participated in our  
673 survey. We also want to express our gratitude to Andreas Reis and Katherine Littler of the Health  
674 Ethics and Governance Unit, World Health Organization, and to the following members of the World  
675 Health Organization COVID-19 Ethics and Governance Working Group, for their inputs on the survey  
676 instrument and manuscript: Aasim Ahmad, Thalia Arawi, Caesar Atuire, Oumou Bah-Sow, Anant  
677 Bhan, Ingrid Callies, Angus Dawson, Jean-François Delfraissy, Ezekiel Emanuel, Ruth Faden, Tina  
678 Garanis-Papadatos, Prakash Ghimire, Dirceu Greco, Calvin Ho, Patrik Hummel, Zubairu Iliyasu,  
679 Mohga Kamal-Yanni, Sharon Kaur, So Yoon Kim, Sonali Kochhar, Ruipeng Lei, Ahmed Mandil,  
680 Julian März, Ignacio Mastroleo, Roli Mathur, Signe Mežinska, Ryoko Miyazaki-Krause, Keymanthri  
681 Moodley, Suerie Moon, Michael Parker, Carla Saenz, G. Owen Schaefer, Ehsan Shamsi-Gooshki,  
682 Jerome Singh, Beatriz Thomé, Teck Chuan Voo, Jonathan Wolff, and Xiaomei Zhai.

683

684 This project was funded by a Canadian Institutes of Health Research grant (#C150-2019-11).

685

686

687 **REFERENCES**

688

- 689 1. Aarons D. Addressing the challenge for expedient ethical review of research in disasters and  
690 disease outbreaks. *Bioethics*. 2019;33: 343–346. doi:10.1111/bioe.12543
- 691 2. Alirol E, Kuesel AC, Guraiib MM, De la Fuente-Núñez V, Saxena A, Gomes MF. Ethics review  
692 of studies during public health emergencies - The experience of the WHO ethics review  
693 committee during the Ebola virus disease epidemic. *BMC Med Ethics*. 2017;18: 1–12.  
694 doi:10.1186/s12910-017-0201-1
- 695 3. Council for International Organizations of Medical Sciences, World Health Organization.  
696 *International Ethical Guidelines for Health-related Research Involving Humans*. Fourth Ed.  
697 Geneva: Council for International Organizations of Medical Sciences; 2016.
- 698 4. Schopper D, Upshur R, Matthys F, Singh JA, Bandewar SS, Ahmad A, et al. Research ethics  
699 review in humanitarian contexts: The experience of the independent ethics review board of  
700 Médecins Sans Frontières. *PLoS Med*. 2009;6: 1–6. doi:10.1371/journal.pmed.1000115
- 701 5. Schopper D, Ravinetto R, Schwartz L, Kamaara E, Sheel S, Segelid MJ, et al. Research ethics  
702 governance in times of Ebola. *Public Health Ethics*. 2017;10: 49–61. doi:10.1093/phe/phw039
- 703 6. Tansey CM, Herridge MS, Heslegrave RJ, Lavery J V. A framework for research ethics review  
704 during public emergencies. *Can Med Assoc J*. 2010;182: 1533–1537. doi:10.1503/cmaj.090976
- 705 7. Canadian Institutes of Health Research, Natural Sciences and Engineering Council of Canada,  
706 Social Sciences and Humanities Research Council. *Tri-Council Policy Statement: Ethical  
707 Conduct for Research Involving Humans*. 2018. Available: [https://ethics.gc.ca/eng/tcps2-  
708 eptc2\\_2018\\_chapter6-chapitre6.html#d](https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter6-chapitre6.html#d)

- 709 8. London AJ, Kimmelman J. Against pandemic research exceptionalism. *Science* (1979).  
710 2020;368: 476–477. doi:10.1126/science.abc1731
- 711 9. Moodley K, Hardie K, Selgelid MJ, Waldman RJ, Strebel P, Rees H, et al. Ethical considerations  
712 for vaccination programmes in acute humanitarian emergencies. *Bull World Health Organ*.  
713 2013;91: 290–297. doi:10.2471/BLT.12.113480
- 714 10. Hashemi A, Bahmani F, Tehrani SS, Forouzandeh M, Koohpayehzadeh J, Ashrafi M, et al.  
715 Ethical considerations and interdisciplinary approach to research on COVID-19 pandemic: The  
716 response of Iran University of Medical Sciences. *Med J Islam Repub Iran*. 2020;34: 1–4.  
717 doi:10.34171/mjiri.34.87
- 718 11. Lencucha R, Neupane S. The use, misuse and overuse of the “low-income and middle-income  
719 countries” category. *BMJ Glob Health*. 2022;7. doi:10.1136/bmjgh-2022-009067
- 720 12. Schneider CE. *The Censor’s Hand: The Misregulation of Human-Subject Research*. 1st edition.  
721 Cambridge, Massachusetts: The MIT Press; 2015.
- 722 13. Kotsis S V., Chung KC. Institutional review boards: What’s old? what’s new? what needs to  
723 change? *Plast Reconstr Surg*. 2014;133: 439–445. doi:10.1097/01.prs.0000436846.00247.73
- 724 14. Stryjewski TP, Kalish BT, Silverman B, Lehmann LS. The Impact of Institutional Review  
725 Boards (IRBs) on clinical innovation: A survey of investigators and IRB members. *J Empir Res*  
726 *Hum Res Ethics*. 2015;10: 481–487. doi:10.1177/1556264615614936
- 727 15. Whitney SN. Institutional review boards: A flawed system of risk management. *Res Ethics*.  
728 2016;12: 182–200. doi:10.1177/1747016116649993



- 729 16. Bauer A, Eskat A, Ntekim A, Wong C, Eberle D, Hedayati E, et al. How COVID-19 changed  
730 clinical research strategies: a global survey. *J Int Med Res.* 2022;50.  
731 doi:10.1177/03000605221093179
- 732 17. Canario Guzmán JA, Orlich J, Mendizábal-Cabrera R, Ying A, Vergès C, Espinoza E, et al.  
733 Strengthening research ethics governance and regulatory oversight in Central America and the  
734 Dominican Republic in response to the COVID-19 pandemic: a qualitative study. *Health Res*  
735 *Policy Syst.* 2022;20. doi:10.1186/s12961-022-00933-z
- 736 18. Zhang H, Shao F, Gu J, Li L, Wang Y. Ethics Committee Reviews of Applications for Research  
737 Studies at 1 Hospital in China During the 2019 Novel Coronavirus Epidemic. *JAMA.* 2020;323:  
738 1844–1846. doi:10.1001/jama.2020.3786
- 739 19. Sisa I, Mena B, Teran E. The negative impact of ad hoc committees for ethical evaluation: The  
740 case of COVID-19-related research in Ecuador. *Dev World Bioeth.* 2021;21: 3–6.  
741 doi:10.1111/dewb.12307
- 742 20. Marzouk D, Sharawy I, Nakhla I, El Hodhod M, Gadallah H, El-Shalakany A, et al. Challenges  
743 During Review of COVID-19 Research Proposals: Experience of Faculty of Medicine, Ain  
744 Shams University Research Ethics Committee, Egypt. *Front Med (Lausanne).* 2021;8: 715796–  
745 715804. doi:10.3389/fmed.2021.715796
- 746 21. Faust A, Sierawska A, Krüger K, Wisgalla A, Hasford J, Strech D. Challenges and proposed  
747 solutions in making clinical research on COVID-19 ethical: a status quo analysis across German  
748 research ethics committees. *BMC Med Ethics.* 2021;22. doi:10.1186/s12910-021-00666-8

- 749 22. Joshi SG, Safai AA, Barve SS. Experience of the selected Ethics Committee of Pune city  
750 regarding the review of COVID-19 protocols during the pandemic. *Perspect Clin Res.* 2023;14:  
751 43–44. doi:10.4103/picr.picr\_2\_22
- 752 23. Kadam A, Patil S, Sane S, Shahabuddin S, Panda S. Challenges faced by ethics committee  
753 members in India during COVID-19 pandemic: A mixed-methods exploration. *Indian J Med*  
754 *Res.* 2022;155: 461–471. doi:10.4103/ijmr.ijmr\_1095\_22
- 755 24. Mukherjee S, Samajdar S, Tripathi R, Tripathi S. Functioning of Institutional Ethics Committees  
756 during the COVID-19 pandemic: An opinion survey. *Perspect Clin Res.* 2022;13: 118–119.  
757 doi:10.4103/picr.PICR\_103\_21
- 758 25. Sheehy A, Ralph James J, Horgan M. Implementing a National Approach to Research Ethics  
759 Review during a Pandemic – the Irish Experience. *HRB Open Res.* 2020;3: 63.  
760 doi:10.12688/hrbopenres.13146.1
- 761 26. Hinga A, Jeena L, Awuor E, Kahindi J, Munene M, Kinyanjui S, et al. Pandemic preparedness  
762 and responsiveness of research review committees: lessons from review of COVID-19 protocols  
763 at KEMRI Wellcome Trust Research Programme in Kenya. *Wellcome Open Res.* 2022;7: 75.  
764 doi:10.12688/wellcomeopenres.17533.1
- 765 27. Kudaibergenova T, Ibrahim M, Jain N, Vetra J. Documentary Assessment of the Abilities of  
766 Kyrgyzstan’s Research Ethics Committees During Public Health Emergency and Non-  
767 Emergency Situations. *J Empir Res Hum Res Ethics.* 2023;18: 99–108.  
768 doi:10.1177/15562646231176711

- 769 28. Palmero A, Carracedo S, Cabrera N, Bianchini A. Governance frameworks for COVID-19  
770 research ethics review and oversight in Latin America: an exploratory study. *BMC Med Ethics*.  
771 2021;22: 147–156. doi:10.1186/s12910-021-00715-2
- 772 29. Ijkema R, Janssens MJPA, van der Post JAM, Licht CM. Ethical review of COVID-19 research  
773 in the Netherlands; a mixed-method evaluation among medical research ethics committees and  
774 investigators. *PLoS One*. 2021;16: e0255040. doi:10.1371/journal.pone.0255040
- 775 30. Shekhani S, Iqbal S, Jafarey A. Adapting the ethical review process for COVID-19 research:  
776 reviewers' perspectives from Pakistan. *East Mediterr Health J*. 2021;27: 1045–1051.  
777 doi:10.26719/emhj.21.053
- 778 31. Burgess T, Rennie S, Moodley K. Key ethical issues encountered during COVID-19 research: a  
779 thematic analysis of perspectives from South African research ethics committees. *BMC Med*  
780 *Ethics*. 2023;24: 11–24. doi:10.1186/s12910-023-00888-y
- 781 32. Rossouw TM, Wassenaar D, Kruger M, Blockman M, Hunter A, Burgess T. Research ethics  
782 support during the COVID-19 epidemic: a collaborative effort by South African Research Ethics  
783 Committees. *S Afr Health Rev*. 2021;2021: 163–172.
- 784 33. Ekmekci PE, Güner MD, Buruk B, Güneş B, Arda B, Görkey Ş. Challenges and practices arising  
785 during public health emergencies: A qualitative survey on ethics committees. *Dev World Bioeth*.  
786 2023;23: 23–33. doi:10.1111/dewb.12345
- 787 34. Ford DE, Johnson A, Nichols JJ, Rothwell E, Dubinett S, Naeim A. Challenges and lessons  
788 learned for institutional review board procedures during the COVID-19 pandemic. *J Clin Transl*  
789 *Sci*. 2021;5: e107. doi:10.1017/cts.2021.27

- 790 35. Sisk BA, Baldwin K, Parsons M, DuBois JM. Ethical, regulatory, and practical barriers to  
791 COVID-19 research: A stakeholder-informed inventory of concerns. *PLoS One*. 2022;17:  
792 e0265252. doi:10.1371/journal.pone.0265252
- 793 36. Taylor HA, Serpico K, Lynch HF, Baumann J, Anderson EE. A snapshot of U.S. IRB review of  
794 COVID-19 research in the early pandemic. *J Clin Transl Sci*. 2021;5: e205.  
795 doi:10.1017/cts.2021.848
- 796 37. World Health Organization. Guidance for managing ethical issues in infectious disease  
797 outbreaks. Geneva; 2016. Available: <https://apps.who.int/iris/handle/10665/250580>
- 798 38. World Health Organization. Key criteria for the ethical acceptability of COVID-19 human  
799 challenge studies 6 May 2020. 2020. Available: <https://apps.who.int/iris/handle/10665/331976>
- 800 39. World Health Organization. Guidance for research ethics committees for rapid review of  
801 research during public health emergencies. 2020. Available:  
802 <https://apps.who.int/iris/handle/10665/332206>
- 803 40. World Health Organization. Ethical standards for research during public health emergencies:  
804 Distilling existing guidance to support COVID-19 R&D. *Journal of Infectious Diseases*. 2020.  
805 Available: <https://apps.who.int/iris/handle/10665/331507>
- 806 41. Pan-American Health Organization. Catalyzing ethical research in emergencies: Ethics  
807 guidance, lessons learned from the COVID-19 pandemic, and pending agenda. 2022. Available:  
808 <https://iris.paho.org/handle/10665.2/56139>
- 809 42. Pan-American Health Organization. Template and operational guidance for the ethics review and  
810 oversight of COVID-19-related research. 2020. Available:  
811 <https://iris.paho.org/handle/10665.2/52086>

- 812 43. Pan-American Health Organization. Guidance and strategies to streamline ethics review and  
813 oversight of COVID-19-related research. 2020. Available:  
814 <https://iris.paho.org/handle/10665.2/52089>
- 815 44. Pan-American Health Organization. Guidance for ethics oversight of COVID-19 research in  
816 response to emerging evidence. 2020. Available: <https://iris.paho.org/handle/10665.2/53021>
- 817 45. World Health Organization. WHO tool for benchmarking ethics oversight of health-related  
818 research with human participants (Draft). Geneva; 2022. Available:  
819 [https://www.who.int/publications/m/item/who-tool-for-benchmarking-ethics-oversight-of-](https://www.who.int/publications/m/item/who-tool-for-benchmarking-ethics-oversight-of-health-related-research-with-human-participants)  
820 [health-related-research-with-human-participants](https://www.who.int/publications/m/item/who-tool-for-benchmarking-ethics-oversight-of-health-related-research-with-human-participants)

821

822

823

## 824 **SUPPORTING INFORMATION**

### 825 **S1 Appendix. Qualtrics questionnaire**

### 826 **S2 Appendix. Supplementary Tables**

- 827 • **Table S 1.** World Health Organization region for which ethics review was provided
- 828 • **Table S 2.** Length of experience of participants as ethics review committee members
- 829 • **Table S 3.** Number of ethics review committees in which participants were involved during the  
830 COVID-19 pandemic
- 831 • **Table S 4.** Simultaneous involvement with multiple ethics review committees
- 832 • **Table S 5.** Presence of additional support for the operation of ethics review committee during  
833 the COVID-19 pandemic
- 834 • **Table S 6.** Additional support of ethics review committee, by type
- 835 • **Table S 7.** Pre-pandemic financial planning with provisions for support of ethics review  
836 committees during a public health emergency
- 837 • **Table S 8.** Modification of existing procedures or policies
- 838 • **Table S 9.** Modified procedures and policies
- 839 • **Table S 10.** Design and implementation of new procedures and policies
- 840 • **Table S 11.** New procedures and policies

- 841 • **Table S 12.** Opinions on whether to permanently put into effect modifications or innovations to  
842 operating procedures implemented during the COVID-19 pandemic
- 843 • **Table S 13.** Modifications or innovations to operating procedures implemented during the  
844 COVID-19 pandemic that should be permanently put into effect
- 845 • **Table S 14.** Presence of support to permanently implement modifications or innovations  
846 established during the COVID-19 pandemic
- 847 • **Table S 15.** Presence of internal policies, procedures, or guidelines
- 848 • **Table S 16.** Presence of external policies, procedures, or guidelines
- 849 • **Table S 17.** Extent of change in the volume of protocols reviewed during the pandemic
- 850 • **Table S 18.** Time it took before the COVID-19 pandemic for research protocols to be approved,  
851 from the time of initial submission to full approval
- 852 • **Table S 19.** Length of time that ethics review committee members took to complete review of  
853 research protocols during the COVID-19 pandemic
- 854 • **Table S 20.** Total time to approval of COVID-19-related research protocols
- 855 • **Table S 21.** Total time to approval for non-COVID-19-related research protocols
- 856 • **Table S 22.** Presence of external pressure on ethics review committees to approve or reject  
857 specific COVID-19 research protocols
- 858 • **Table S 23.** Prioritization of COVID-19 related research over non-COVID-19-related protocols
- 859 • **Table S 24.** Prioritization of some types of COVID-19-related research over others
- 860 • **Table S 25.** Ensuring quorum
- 861 • **Table S 26.** Presence of measures to ensure continuity of adequate review of research protocols  
862 in case existing members became unavailable due to the pandemic
- 863 • **Table S 27.** Addition of new members to accelerate protocol review during the COVID-19  
864 pandemic
- 865 • **Table S 28.** Addition of new members with specific expertise to address novel areas of research  
866 or provide enhanced scrutiny of research protocols during the COVID-19 pandemic
- 867 • **Table S 29.** Consultation of expert non-members to address novel areas of research or provide  
868 enhanced scrutiny of research protocols during the COVID-19 pandemic
- 869 • **Table S 30.** National and international collaboration among ethics review committees to  
870 standardize emergency operations and procedures during the COVID-19 pandemic
- 871 • **Table S 31.** Presence of strategies to harmonize multiple review processes
- 872 • **Table S 32.** Reliance on established procedures to recognize and validate research protocol  
873 reviews conducted by other ethics committees
- 874 • **Table S 33.** Collaboration with scientific committees that pre-reviewed or prioritized pandemic-  
875 related research protocols
- 876 • **Table S 34.** Presence of centralized ethics review of research protocols for multicentre studies  
877 related to COVID-19
- 878 • **Table S 35.** Formation of Joint Scientific Advisory Committees, Data Safety Review  
879 Committees, Data Access Committees, or a Joint Ethics Review Committee




Figure 1